Trial Profile

A Study to Evaluate Metformin Reformulation for the Treatment of Degenerative Eye Disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 09 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Metformin (Primary)
Indications Eye disorders; Wet age-related macular degeneration
Focus Adverse reactions
Sponsors Curative Biotechnology

Most Recent Events

03 May 2022 According to a Curative Biotechnology media release, under a Cooperative Research and Development Agreement (CRADA), the National Eye Institute (NEI) and company will collaborate to evaluate Metformin ocular formulation in clinical studies for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.
12 Feb 2021 New trial record
04 Feb 2021 According to a Connectyx Technologies media release, the company anticipates being prepared for human testing of Metformin reformulation by third quarter of 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com